Liraglutide Attenuates Myocardial Ischemia/Reperfusion Injury Through the Inhibition of Necroptosis by Activating GLP-1R/PI3K/Akt Pathway.
Liraglutide透過激活GLP-1R/PI3K/Akt途徑抑制壞死激素,減輕心肌缺血/再灌注損傷。
Cardiovasc Toxicol 2023-04-28
An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis.
新型抗糖尿病藥物類別的心臟保護效應概述:著重於炎症、氧化壓力和纖維化。
Int J Mol Sci 2023-11-02
Beyond the Cardiovascular Effects of Glucagon-like Peptide-1 Receptor Agonists: Body Slimming and Plaque Stabilization. Are New Statins Born?
糖尿病藥物胰高血糖素樣肽-1受體激動劑的心血管效應之外:體重減輕和斑塊穩定。新的他汀藥誕生?
Biomolecules 2024-01-04
Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease.
葡萄糖樣肽-1 受體激動劑:治療動脈粥樣硬化心血管疾病的新策略和治療靶點。
Front Pharmacol 2024-05-10
Peptides Are Cardioprotective Drugs of the Future: The Receptor and Signaling Mechanisms of the Cardioprotective Effect of Glucagon-like Peptide-1 Receptor Agonists.
肽類是未來心臟保護藥物:瘦素樣肽-1受體激動劑的心臟保護效應的受體和信號機制。
Int J Mol Sci 2024-05-13
Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs.
GLP-1 受體激動劑的心血管保護特性:不僅僅是糖尿病和減重藥物。
J Clin Med 2024-08-29